Full Press Release Details
VANCOUVER, British Columbia and WARMINSTER, Pa., June 02, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company will be participating in the following investor conferences:
Jefferies 2017 Global Healthcare Conference, June 6-9, 2017, New York, and
JMP Securities Life Sciences Conference, June 20-21, 2017, New York.
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.